首页> 外文期刊>Expert opinion on therapeutic targets >Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease
【24h】

Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease

机译:评论:非酒精性脂肪肝疾病的新型治疗靶点

获取原文
获取原文并翻译 | 示例
           

摘要

The authors congratulate Eguchi et al. for their comprehensive review on novel findings related to the pathobiology of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), such as angiogenesis and fibrosis, the inflammasome complex, incretins and modulation of dietary lipids. It is worth looking at some current interventions. The therapeutic approach of the patient with NAFLD should be multifactorial. The authors found after a 54-week multifactorial intervention (diet plus drugs, mainly hypolipidemic) in a randomized study with 186 NAFLD patients that 67% of participants on atorvastatin, 42% on fenofibrate and 70% on combination treatment no longer had biochemical plus ultrasonographic evidence of NAFLD (p < 0.05 vs baseline for all) [2]. The Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) study included 1123 metabolic syndrome patients, while 326 had NAFLD [3].
机译:作者对Eguchi等人表示祝贺。他们对与非酒精性脂肪肝疾病(NAFLD)和非酒精性脂肪性肝炎(NASH)的病理生物学相关的新发现进行了全面的综述,例如血管生成和纤维化,炎症小体,肠降血糖素和饮食脂质的调节。值得关注一些当前的干预措施。 NAFLD患者的治疗方法应该是多因素的。作者在一项针对186名NAFLD患者的随机研究中,经过54周的多因素干预(饮食加药物,主要是降血脂)后,发现67%的阿托伐他汀,42%的非诺贝特和70%的联合治疗参与者不再接受生化和超声检查NAFLD的证据(相对于所有基线,p <0.05)[2]。在没有可察觉的糖尿病的情况下评估代谢综合征的治疗效果(ATTEMPT)研究包括1123例代谢综合征患者,而326例患有NAFLD [3]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号